ES2546612T3 - Vacuna contra la viruela - Google Patents

Vacuna contra la viruela Download PDF

Info

Publication number
ES2546612T3
ES2546612T3 ES02728888.5T ES02728888T ES2546612T3 ES 2546612 T3 ES2546612 T3 ES 2546612T3 ES 02728888 T ES02728888 T ES 02728888T ES 2546612 T3 ES2546612 T3 ES 2546612T3
Authority
ES
Spain
Prior art keywords
virus
variolovacunal
strain
pharmaceutical composition
dryvax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02728888.5T
Other languages
English (en)
Spanish (es)
Inventor
Richard A. Weltzin
Thomas P. Monath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
Sanofi Pasteur Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics LLC filed Critical Sanofi Pasteur Biologics LLC
Application granted granted Critical
Publication of ES2546612T3 publication Critical patent/ES2546612T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES02728888.5T 2001-04-23 2002-04-23 Vacuna contra la viruela Expired - Lifetime ES2546612T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/840,751 US6723325B1 (en) 2001-04-23 2001-04-23 Smallpox vaccine
US840751 2001-04-23
PCT/US2002/012616 WO2002085411A1 (en) 2001-04-23 2002-04-23 Smallpox vaccine

Publications (1)

Publication Number Publication Date
ES2546612T3 true ES2546612T3 (es) 2015-09-25

Family

ID=25283120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02728888.5T Expired - Lifetime ES2546612T3 (es) 2001-04-23 2002-04-23 Vacuna contra la viruela

Country Status (19)

Country Link
US (2) US6723325B1 (https=)
EP (1) EP1381389B1 (https=)
JP (1) JP4397591B2 (https=)
KR (1) KR20040063083A (https=)
CN (1) CN1527722A (https=)
AU (1) AU2002258910B2 (https=)
BR (1) BR0209145A (https=)
CA (1) CA2444747C (https=)
CZ (1) CZ305819B6 (https=)
EA (1) EA007656B1 (https=)
ES (1) ES2546612T3 (https=)
HU (1) HU228401B1 (https=)
IL (2) IL158549A0 (https=)
MA (1) MA26270A1 (https=)
MX (1) MXPA03009711A (https=)
NZ (1) NZ529265A (https=)
PL (1) PL212117B1 (https=)
WO (1) WO2002085411A1 (https=)
ZA (1) ZA200309084B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
MX2009004862A (es) 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
KR100859345B1 (ko) * 2006-12-12 2008-09-19 씨제이제일제당 (주) 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
RU2496149C1 (ru) * 2012-06-19 2013-10-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ оценки противооспенной активности лечебно-профилактических препаратов
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5614193A (en) * 1991-11-14 1997-03-25 The United States Of America As Represented By The Secretary Of The Army Hantavirus vaccine
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine

Also Published As

Publication number Publication date
US7115270B2 (en) 2006-10-03
JP4397591B2 (ja) 2010-01-13
EP1381389A1 (en) 2004-01-21
HUP0303878A3 (en) 2010-01-28
KR20040063083A (ko) 2004-07-12
WO2002085411A1 (en) 2002-10-31
MXPA03009711A (es) 2005-03-07
US6723325B1 (en) 2004-04-20
PL373958A1 (en) 2005-09-19
AU2002258910B2 (en) 2007-10-25
EP1381389B1 (en) 2015-08-26
CA2444747A1 (en) 2002-10-31
US20060153873A1 (en) 2006-07-13
CZ20033184A3 (cs) 2004-04-14
ZA200309084B (en) 2005-01-26
HU228401B1 (en) 2013-03-28
CA2444747C (en) 2018-04-17
PL212117B1 (pl) 2012-08-31
NZ529265A (en) 2006-04-28
HK1062804A1 (zh) 2004-11-26
EA007656B1 (ru) 2006-12-29
EA200301151A1 (ru) 2004-10-28
IL158549A (en) 2009-07-20
MA26270A1 (fr) 2004-09-01
BR0209145A (pt) 2005-04-19
IL158549A0 (en) 2004-05-12
HUP0303878A2 (hu) 2004-03-01
CN1527722A (zh) 2004-09-08
EP1381389A4 (en) 2004-07-28
JP2005503126A (ja) 2005-02-03
CZ305819B6 (cs) 2016-03-30

Similar Documents

Publication Publication Date Title
Sikes et al. Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine
Henle Interference phenomena between animal viruses: a review
ES2546612T3 (es) Vacuna contra la viruela
Fooks et al. New human rabies vaccines in the pipeline
Rupprecht et al. Ineffectiveness and comparative pathogenicity of attenuated rabies virus vaccines for the striped skunk (Mephitis mephitis)
US7645456B2 (en) Vaccinia virus strains
Kaplan Vaccinia virus: a suitable vehicle for recombinant vaccines?
Gellin et al. Measles: state of the art and future directions
AU2002258910A1 (en) Smallpox vaccine
Jarouliya et al. Developing Vaccine Against COVID-19 and Immune Response
Lane The current and future landscape of smallpox vaccines
ES2557315T3 (es) Nuevo virus de la gripe
Golahdooz et al. Comparison of immune responses following intradermal and intramuscular rabies vaccination methods
Naraporn et al. Immune response to rabies booster vaccination in subjects who had postexposure treatment more than 5 years previously
Hadi et al. A review of some coronavirus vaccines
HK1062804B (en) Smallpox vaccine
Tannock et al. Immunization against influenza by the ocular route
NZ567684A (en) Prime boost vaccine for the protection of equines against equine influenza
Awais et al. Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review
Melnick Poliomyelitis vaccination: what are the options?
Ben-Yedidia A peptide-based vaccine against influenza
Smedberg Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors
Berendt et al. Evaluation of Commerically Prepared Vaccines for Experimentally Induced Type A/NJ Virus Influenza Infections in Mice and Squirrel Monkeys.
Yilma A vaccinia virus recombinant vaccine for rinderpest
World Health Organization Working Group on Vaccine Development and Vaccine Strategies for Japanese Encephalitis, Tokyo, Japan, 10-12 December 1985: report